Guide
CMC readiness for an Investigational New Drug application means the drug substance, drug product, analytical methods, stability program, and manufacturing controls are documented well enough to support the proposed clinical doses. CMC gaps are a frequent source of FDA information requests and pre-submission risk.
CMC readiness is the state where the chemistry, manufacturing, and controls package can support safe administration of the planned clinical study without leaving major characterization or control questions open.
| CMC area | Expected documentation | Readiness signal |
|---|---|---|
| Drug substance | Structure, process, impurity profile, specs | Defined impurity strategy with limits |
| Drug product | Formulation, composition, container/closure | Stable formulation that supports planned use |
| Analytical methods | Identity, assay, purity, potency, qualification | Methods qualified for intended use |
| Stability | Storage conditions, time points, ongoing plan | Covers planned clinical-use period |
| Manufacturing controls | Process description, in-process controls, batch records | Reproducibility across batches |
Reviewers look for a clear description of the substance, its synthetic or biosynthetic route, characterization, and an impurity strategy tied to the toxicology coverage.
The product section should explain the formulation, composition, container/closure, and why the chosen presentation is appropriate for the planned route of administration.
At IND, analytical methods are typically qualified for their intended use. Identity, assay, purity, and — for biologics — potency methods should each have documented performance characteristics.
Stability should cover at least the planned clinical-use period with a justified storage condition. An ongoing stability plan that extends through the study is standard.
Process description, in-process controls, and batch consistency support the case that clinical material is representative of what nonclinical studies evaluated.
CMC readiness means the drug substance, drug product, analytical methods, stability, and manufacturing controls are characterized and documented well enough to support safe administration of the proposed clinical doses and schedule.
Stability data should at least cover the duration of planned clinical use, with a justified storage condition and a plan for ongoing stability monitoring. Limited stability is a common source of FDA information requests.
Methods are typically qualified rather than fully validated at IND, but they should be suitable for their intended use, with documented specificity, accuracy, and precision appropriate to the phase of development.
Request an IND readiness assessment connected to Alenvo.
Check IND Readiness